600422.SH
昆药集团
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 8.31
−2.69%Year over year
Reported trailing growth
- Revenue
- -28.2%
- EBITDA
- —
- EBIT
- -81.5%
- EPS
- -81.1%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -6.6%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -7.4%
- EBITDA
- -4.4%
- EBIT
- -3.4%
- Net income
- -3.0%
- EPS
- -3.4%
- Free cash flow
- +9.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026